North Dakota Medicaid
Drug Utilization Review (DUR) Meeting Minutes
March 4, 2020

Members Present: Peter Woodrow, Corey Miller, Mary Aaland, Tanya Schmidt, Andrea Honeyman, Gabriela Balf, Laura Schield, Amy Werremeyer

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy, LeNeika Roehrich

Old Business

Chair A. Honeyman called the meeting to order at 1:05 p.m. Chair A. Honeyman asked for a motion to approve the minutes of the December meeting. P. Woodrow moved that the minutes be approved, and L. Schield seconded the motion. The chair called for a voice vote to approve the minutes. The motion passed with no audible dissent.

DHS Announcements

B. Joyce announced a change made to first-fill requirements for agents used to treat attention deficit hyperactivity disorder (ADHD). The requirement has been changed to a maximum first fill of 14 days to a limit of 10 days.

Update On North Dakota Medicaid Expansion Population Carve-Out

B. Joyce updated the Board on the transition of the management of pharmacy benefits for the North Dakota Medicaid Expansion population. He described selected claims processing edits that had been in place for the fee-for-service population that had been turned off beginning January 1st in order to allow for continuation of care for expansion patients during the transition.

Review Top 15 Therapeutic Categories/Top 25 Drugs

B. Joyce presented the quarterly review of the top 15 therapeutic classes by total cost of claims, top 25 drugs based on number of claims, and top 25 drugs based on claims cost for the 4th quarter of 2019. M. Aaland inquired about reimbursement for IHS claims, and B. Joyce explained the process for how ND Medicaid pays for these claims.

PDL/PA Criteria Updates

A. Murphy shared with the Board the changes made to the Preferred Drug List since the most recent version of the Preferred Drug List was posted. Specifically, highlighted were changes made with the addition of Ubrelvy to the Migraine Treatment class, Davigo to the Sedative/Hypnotics class, and Talicia to the H. Pylori class. Tim Wardell of Allergan provided a brief presentation on Ubrelvy during public comment. M. Aaland inquired about the cost of Ubrelvy and T. DeRuiter gave pricing information based on average wholesale price. G. Balf asked whether a re-trial of prior sedative/hypnotic agents would be required if the most recent failure was not within the past 30-days, and A. Murphy explained that retrials are not required if the medication was discontinued due to lack of efficacy or intolerable adverse effects. When a new version of the PDL is published and posted to the website, all updates/changes made since the last version are called out at the top of the document itself.

Second Review of Glucagon Agents
A motion and second was made at the December meeting to place glucagon agents on prior authorization. The topic was brought up for a second review with prior authorization presented by T. DeRuiter. There was no public comment. M. Aaland inquired about current glucagon utilization in the North Dakota Medicaid population, which T. DeRuiter provided. Chair A. Honeyman called for a voice vote and the motion passed with no audible dissent.

Second Review of Ofev for Interstitial Lung Disease
A motion and second was previously made to place agents for the treatment of idiopathic pulmonary fibrosis/interstitial lung disease on prior authorization. The topic was brought up for a second review with prior authorization criteria including this indication presented by A. Murphy. M. Aaland inquired as to whether limiting coverage to those prescribed Ofev by or in consultation with a pulmonologist or rheumatologist would apply to just physicians with that specialty, and B. Joyce and A. Murphy explained that it would. Dan Joy of Boehringer Ingelheim presented during time for public comment. Chair A. Honeyman called for a voice vote and the motion passed with no audible dissent.

New Business
Review of Conjupri
T. DeRuiter presented a review of the newly approved drug, Conjupri to the Board. A motion was made by L. Schield for DHS to create PA criteria for the use of these agents and manage these medications through prior authorization. The motion was seconded by P. Woodrow. Criteria for Conjupri will be presented and voted on by the DUR Board at the next meeting.

Discussion on Spinraza and Zolgensma
A. Murphy and B. Joyce presented on how DHS is currently managing utilization of Spinraza and Zolgensma, including presenting the criteria for coverage of these agents. Eric Cox and Beth Pegram of AveXis spoke about the role of Zolgensma in treatment of SMA. The Board inquired about cost of the medications, which B. Joyce provided based on public pricing data.

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, and new warnings. T. DeRuiter presented the new RDUR criteria and explained the RDUR profile review process. M. Aaland inquired as to whether the RDUR criteria is be overly burdensome to providers due to the high number of RDUR criteria ND Medicaid currently has approved. T. DeRuiter explained that the RDUR profile review process is targeted to a select few criteria each month to prevent alert fatigue. L. Schield moved to approve the new criteria and P. Woodrow seconded the motion. The motion passed with no audible dissent. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles.

Adjournment and Upcoming Meeting Date
Chair A. Honeyman adjourned the meeting at 3:15 pm. The next DUR Board meeting will be held June 3, 2020 at 1:00 pm at the State Capitol building in a meeting room to be announced at a later date.